Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have been given a consensus recommendation of “Hold” by the six analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $24.50.
A number of research firms have commented on AXDX. Zacks Investment Research downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Thursday. Piper Jaffray Companies reiterated a “buy” rating and set a $24.00 target price on shares of Accelerate Diagnostics in a research report on Tuesday, August 7th. BidaskClub downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Friday, July 6th. ValuEngine upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday, June 11th. Finally, Craig Hallum began coverage on Accelerate Diagnostics in a research report on Thursday, May 24th. They set a “hold” rating and a $25.00 target price on the stock.
In other news, Director Jack W. Schuler bought 65,000 shares of the firm’s stock in a transaction on Monday, May 14th. The shares were bought at an average cost of $19.97 per share, for a total transaction of $1,298,050.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 49.30% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the company. Cornerstone Wealth Management LLC purchased a new stake in shares of Accelerate Diagnostics in the second quarter valued at $210,000. Lee Financial Co purchased a new stake in shares of Accelerate Diagnostics in the first quarter valued at $128,000. MetLife Investment Advisors LLC purchased a new stake in shares of Accelerate Diagnostics in the fourth quarter valued at $297,000. Cowen Inc. purchased a new stake in shares of Accelerate Diagnostics in the first quarter valued at $267,000. Finally, Thompson Investment Management Inc. lifted its position in shares of Accelerate Diagnostics by 10.6% in the second quarter. Thompson Investment Management Inc. now owns 31,200 shares of the medical research company’s stock valued at $696,000 after acquiring an additional 3,000 shares in the last quarter. Institutional investors and hedge funds own 47.49% of the company’s stock.
Accelerate Diagnostics remained flat at $$22.25 on Tuesday, MarketBeat reports. The company had a trading volume of 122,810 shares, compared to its average volume of 209,691. Accelerate Diagnostics has a 52-week low of $16.75 and a 52-week high of $30.35. The company has a current ratio of 27.12, a quick ratio of 26.44 and a debt-to-equity ratio of 1.22.
Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings data on Monday, August 6th. The medical research company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.06). Accelerate Diagnostics had a negative return on equity of 67.75% and a negative net margin of 1,405.87%. The business had revenue of $1.69 million for the quarter, compared to analyst estimates of $2.17 million. equities analysts predict that Accelerate Diagnostics will post -1.66 EPS for the current fiscal year.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Further Reading: Understanding Relative Strength Index
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.